medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Фев. 20, 2024
Abstract
Objective
This
proof-of-principle
pharmacovigilance
study
used
Electronic
Health
Record
(EHR)
data
to
examine
the
safety
of
sotrovimab,
paxlovid
and
molnupiravir
in
prehospital
treatment
Covid-19.
Method
With
NHS
England
approval,
we
conducted
an
observational
cohort
using
OpenSAFELY-TPP,
a
secure
software-platform
which
executes
analyses
across
EHRs
for
24
million
people
England.
High-risk
individuals
with
Covid-19
eligible
were
included.
Adverse
events
(AEs)
categorised
into
drug’s
Summary
Product
Characteristics
(SmPC),
drug-reactions
immune-mediated.
Cox
models
compared
risk
treatments.
A
pre-pandemic
record
analysis
was
performed
comparative
purposes.
Results
Between
2021-2023,
37,449
patients
received
or
whilst
109,647
made
up
eligible-but-untreated
population.
The
29-day
rates
AEs
low:
SmPC
0.34
per
1000
patient-years
(95%CI
0.32-0.36);
0.01(95%
CI0.01-0.02)
immune-mediated
0.03(95%CI
0.03-0.04),
similar
lower
than
period.
Compared
but
untreated
population,
sotrovimab
associated
AE
[adjHR
1.36(95%CI
1.15-1.62)
1.28(95%CI
1.05-1.55),
respectively],
2.95(95%CI
1.56-5.55)]
3.22(95%CI
1.86-5.57)].
Conclusion
Sotrovimab,
demonstrate
acceptable
profiles.
Although
greatest
event
Reviews in Medical Virology,
Год журнала:
2024,
Номер
34(4)
Опубликована: Июнь 7, 2024
Abstract
This
systematic
review
and
meta‐analysis
aimed
to
compare
the
effectiveness
safety
of
azvudine
versus
nirmatrelvir/ritonavir
(Paxlovid)
in
treating
coronavirus
disease
2019
(COVID‐19).
The
researchers
conducted
searches
on
PubMed,
Cochrane
Library,
Web
Science,
medRxiv,
Google
Scholar
until
January
2024.
risk
bias
tool
was
utilised
evaluate
quality
included
studies,
data
analysis
performed
using
Comprehensive
Meta‐Analysis
software.
Thirteen
including
4949
patients,
were
analysed.
results
showed
no
significant
difference
between
Paxlovid
groups
terms
mortality
rate
(odds
[OR]
=
0.84,
95%
confidence
interval
[CI]:
0.59–1.21),
negative
polymerase
chain
reaction
(PCR)
conversion
time
(standard
mean
[SMD]
1.52,
CI:
−1.07–4.11),
hospital
stay
(SMD
−0.39,
−1.12–0.33).
However,
a
observed
two
intensive
care
unit
admission
(OR
0.42,
0.23–0.75)
need
for
mechanical
ventilation
0.61,
0.44–0.86)
favour
azvudine.
incidence
adverse
events
group
significantly
lower
0.66,
0.43–0.99).
certainty
evidence
rated
as
low
moderate.
Azvudine
demonstrated
similar
reducing
rates,
PCR
stay.
better
improving
other
outcomes.
Regarding
level
evidence,
further
research
is
needed
validate
or
challenge
these
results.
BMC Infectious Diseases,
Год журнала:
2024,
Номер
24(1)
Опубликована: Июль 19, 2024
Abstract
Background
Camostat
mesylate,
an
oral
serine
protease
inhibitor,
is
a
powerful
TMPRSS2
inhibitor
and
has
been
reported
as
possible
antiviral
treatment
against
COVID-19.
Therefore,
we
aim
to
assess
the
safety
efficacy
of
camostat
mesylate
for
COVID-19
treatment.
Methods
A
systematic
review
meta-analysis
synthesizing
randomized
controlled
trials
from
PubMed,
Scopus,
Embase,
Cochrane,
Web
Science,
clinical
trials.gov,
medrxiv
until
June
2023.
The
outcomes
were
pooled
using
Mean
difference
(MD)
continuous
risk
ratio
(RR)
dichotomous
outcomes.
protocol
registered
in
PROSPERO
with
ID
CRD42023439633.
Results
Nine
RCTs,
including
1,623
patients,
included
this
analysis.
There
was
no
between
placebo
producing
negative
PCR
test
results
at
1–7
days
(RR:
0.76,
95%
CI:
[0.54,
1.06]
P
=
0.1),
8–14
1.02,
[0.84,
1.23]
0.87),
or
15–21
0.99,
[0.82,
1.19]
0.90);
resolution
symptoms
0.94
(95%
0.58,
1.53)
0.81),
0.91,
[0.74,
1.11]
0.33,
),
0.77,
[0.40,
1.51]
0.45);
time
symptom
improvement
(MD:-0.38
weeks
[-1.42,
0.66]
0.47,
I
2
85%).
Conclusion
did
not
improve
patients
COVID-19,
compared
placebo.
PLoS ONE,
Год журнала:
2024,
Номер
19(6), С. e0298772 - e0298772
Опубликована: Июнь 13, 2024
Objective
The
aim
of
this
study
was
to
assess
the
effectiveness
and
safety
azvudine
in
treating
coronavirus
disease
2019
(COVID-19)
caused
by
severe
acute
respiratory
syndrome
2
(SARS-COV-2).
Methods
A
search
carried
out
PubMed,
Cochrane
Library,
Web
Science,
medRxiv,
Google
Scholar
until
October
20,
2023.
risk
bias
tools
were
used
quality
included
studies.
Comprehensive
Meta-Analysis
software
analyze
data.
Results
Twenty-one
studies
including
10,011
patients
examined.
meta-analysis
results
showed
that
standard
care/placebo
(SOC/PBO)
significantly
different
concerning
mortality
rate
(risk
ratio
[RR]
=
0.48,
95%
confidence
interval
[CI]:
0.40
0.57)
negative
polymerase
chain
reaction
(PCR)
conversion
time
(standard
mean
difference
-
0.75,
CI:
-1.29
to—0.21).
However,
two
groups
did
not
show
significant
differences
hospital
stay,
intensive
care
unit
(ICU)
admission,
need
for
mechanical
ventilation
(P
>
0.05).
On
other
hand,
nirmatrelvir-ritonavir
(RR
0.73,
0.58
0.92),
ICU
admission
0.41,
0.21
0.78),
0.67,
0.51
0.89),
but
treatments
PCR
time,
stay
incidence
adverse
events
between
certainty
evidence
rated
as
low
or
moderate.
Conclusions
antiviral
against
SARS-COV-2
is
questionable
with
regard
evidence.
Further
research
should
be
conducted
establish
COVID-19.
Open Forum Infectious Diseases,
Год журнала:
2024,
Номер
11(7)
Опубликована: Июнь 28, 2024
We
evaluated
naturally
occurring
nirmatrelvir-ritonavir
(NTV/r)
resistance-associated
mutations
(RAMs)
among
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
strains
from
Botswana,
a
country
with
no
NTV/r
use
to
date,
in
order
recommend
the
usage
of
agent
for
high-risk
patients
disease
2019
(COVID-19).
Expert Review of Anti-infective Therapy,
Год журнала:
2024,
Номер
22(7), С. 547 - 555
Опубликована: Март 8, 2024
Background
This
study
aims
to
compare
the
effectiveness
and
safety
of
nirmatrelvir/ritonavir
(Paxlovid)
sotrovimab
for
coronavirus
disease
2019
(COVID-19).
